FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4316085742> ?p ?o ?g. }

• W4316085742 endingPage "e1798" @default.
• W4316085742 startingPage "e1798" @default.
• W4316085742 abstract "Introduction: Graves’ orbitopathy is an autoimmune disease that develops in approximately 40% of patients with Graves’ disease. Insulin-like growth factor I receptor (IGF-IR) is overexpressed in this disease and plays a central role in this ophthalmopathy. Teprotumumab is a monoclonal antibody against IGF-IR used for active Graves’ orbitopathy. We report a patient who presented with rectal bleeding and was found to have a reoccurrence of inflammatory bowel disease (IBD) thought to be secondary to recent teprotumumab therapy. Case Description/Methods: A 46-year-old female with a diagnosis of Crohn’s disease, off of therapy for 4 years with endoscopic and histological remission, history of pyoderma gangrenosum, psoriasis, vitiligo, and Graves’ orbitopathy presented to the emergency department for rectal bleeding. On review, the patient had finished teprotumumab infusions 17 days prior to presentation. Following each infusion, she would experience 2 days of self-resolving rectal bleeding. After her last infusion, the bleeding persisted for more than a week leading her to seek medical care. Labs were significant for hemoglobin 11.4, CRP 0.4, and ESR 28. Colonoscopy revealed continuous severe inflammation extending from the dentate line up to the sigmoid colon as well as the presence of a cecal patch. Biopsies showed active proctocolitis with cryptitis, crypt abscesses and lymphoplasmacytosis. Patient was started on solumedrol 20 mg IV every 8 hours. Her symptoms resolved with the IV solumedrol and she was discharged home on a course of oral corticosteroids. Discussion: IGF-1 induces proliferation of regulatory T cells and pauses progression of autoimmune disease in the bowel. Animal models have suggested that IGF-1 is involved in mucosal repair and has an anti-apoptotic function in gut mucosa. Patients with active IBD have reduced levels of IGF-1. Therefore, it could be inferred that the use of teprotumumab, a medication whose method of action is to inhibit this growth factor receptor, may exacerbate or illicit IBD. The drug prescribing information does caution that teprotumumab can trigger exacerbation of the underlying IBD and recommends close monitoring of IBD patients. This case highlights a potentially detrimental side effect and appropriate discussions with patients should be held prior to this medications usage. Ideally the gastroenterologist should be kept abreast of the decision to initiate such therapy to allow for careful monitoring." @default.
• W4316085742 created "2023-01-14" @default.
• W4316085742 creator A5057003369 @default.
• W4316085742 creator A5066696703 @default.
• W4316085742 creator A5070365405 @default.
• W4316085742 date "2022-10-01" @default.
• W4316085742 modified "2023-10-17" @default.
• W4316085742 title "S2736 Insulin-Like Growth Factor I Receptor Inhibitor-Induced Inflammatory Bowel Disease" @default.
• W4316085742 doi "https://doi.org/10.14309/01.ajg.0000867584.64487.57" @default.
• W4316085742 hasPublicationYear "2022" @default.
• W4316085742 type Work @default.
• W4316085742 citedByCount "1" @default.
• W4316085742 countsByYear W43160857422023 @default.
• W4316085742 crossrefType "journal-article" @default.
• W4316085742 hasAuthorship W4316085742A5057003369 @default.
• W4316085742 hasAuthorship W4316085742A5066696703 @default.
• W4316085742 hasAuthorship W4316085742A5070365405 @default.
• W4316085742 hasBestOaLocation W43160857421 @default.
• W4316085742 hasConcept C121608353 @default.
• W4316085742 hasConcept C126322002 @default.
• W4316085742 hasConcept C141071460 @default.
• W4316085742 hasConcept C2778260677 @default.
• W4316085742 hasConcept C2778435480 @default.
• W4316085742 hasConcept C2779134260 @default.
• W4316085742 hasConcept C2780132546 @default.
• W4316085742 hasConcept C2780505380 @default.
• W4316085742 hasConcept C2780520777 @default.
• W4316085742 hasConcept C526805850 @default.
• W4316085742 hasConcept C71924100 @default.
• W4316085742 hasConcept C90924648 @default.
• W4316085742 hasConceptScore W4316085742C121608353 @default.
• W4316085742 hasConceptScore W4316085742C126322002 @default.
• W4316085742 hasConceptScore W4316085742C141071460 @default.
• W4316085742 hasConceptScore W4316085742C2778260677 @default.
• W4316085742 hasConceptScore W4316085742C2778435480 @default.
• W4316085742 hasConceptScore W4316085742C2779134260 @default.
• W4316085742 hasConceptScore W4316085742C2780132546 @default.
• W4316085742 hasConceptScore W4316085742C2780505380 @default.
• W4316085742 hasConceptScore W4316085742C2780520777 @default.
• W4316085742 hasConceptScore W4316085742C526805850 @default.
• W4316085742 hasConceptScore W4316085742C71924100 @default.
• W4316085742 hasConceptScore W4316085742C90924648 @default.
• W4316085742 hasIssue "10S" @default.
• W4316085742 hasLocation W43160857421 @default.
• W4316085742 hasLocation W43160857422 @default.
• W4316085742 hasOpenAccess W4316085742 @default.
• W4316085742 hasPrimaryLocation W43160857421 @default.
• W4316085742 hasRelatedWork W1975032444 @default.
• W4316085742 hasRelatedWork W2028578392 @default.
• W4316085742 hasRelatedWork W2074216669 @default.
• W4316085742 hasRelatedWork W2077443323 @default.
• W4316085742 hasRelatedWork W2087258754 @default.
• W4316085742 hasRelatedWork W2090292636 @default.
• W4316085742 hasRelatedWork W2963825579 @default.
• W4316085742 hasRelatedWork W3087768868 @default.
• W4316085742 hasRelatedWork W4207040206 @default.
• W4316085742 hasRelatedWork W4212847486 @default.
• W4316085742 hasVolume "117" @default.
• W4316085742 isParatext "false" @default.
• W4316085742 isRetracted "false" @default.
• W4316085742 workType "article" @default.